2013 Fiscal Year Final Research Report
Development of novel combined cancer immunotherapy using adoptive naive T cell transfer.
| Project/Area Number |
23590891
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine (including Psychosomatic medicine)
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
ISHIKAWA Takeshi 京都府立医科大学, 医学(系)研究科(研究院), 講師 (90372846)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOKURA Satoshi (財)ルイ・パストゥール医学研究センター, 研究員 (80347442)
ADACHI Satoko 京都府立医科大学, 医学部, 研究員 (90546615)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | がん免疫療法 / ナイーブTリンパ球 / CTLA-4 / 細胞療法 |
|---|
| Research Abstract |
In adoptive cell therapy(ACT), the intrinsic properties of the transferred cell population, particularly its state of differentiation, are considered to be crucial to the success of ACT based approaches, and naive T cells are ideal for ACT because of their in vivo persistence and high proliferative potential.In this study, we evaluated the synergic anti-tumor effect of CTLA-4 blockade combined with ACT considering the state of differentiation of transferred cells in mouse colon cancer model.CTLA-4 blockade combined with naive T-cell transfer showed the strongest antitumor effect among all groups. Moreover, CTLA-4 blockade can drive polarization of tumor-infiltrating T cells toward the T helper 1 lineage and suppress the frequency of Tregs within tumor especially in combination with naive T-cell transfer.These data support the notion that the combination of CTLA-4 blockade and ACT containing a lot of naive cells could expert powerful antitumor effects in clinical setting.
|
